Table of contents
Nausea is the side effect of Wegovy that we think deserves the most careful explanation, because the numbers are easy to misread. It was common in the trials and became less common as treatment went on, though some people still had symptoms later and episodes could return. [2] [3] [4]
Imagine a patient a few weeks into treatment who sends a message late one evening. They’ve felt queasy since their last dose increase, and they want to know whether that’s expected and how long it will last. That’s really three questions: how often nausea happens, when it happens and how long it lasts. The evidence answers each one a little differently, so we’ll take them in turn.
Most of the findings below come from weight-management trials in adults using the weekly semaglutide injection at a target dose of 2.4 mg, the regimen studied for Wegovy. Results for the tablet and the higher-dose injection come from separate studies, so they have their own section.
How common is nausea with Wegovy?
In a pooled analysis of the STEP 1-3 trials, 43.9% of participants assigned to semaglutide reported nausea, compared with 16.1% assigned to placebo. That counts anyone who reported nausea at any point, so it doesn’t mean people felt nauseated every day or after every injection. [2]
Reported nausea during the trials
43.9%
Semaglutide · targeting 2.4 mg
16.1%
Placebo
About these numbers
The STEP 1-3 trials ran for 68 weeks and randomized 2,117 participants to semaglutide and 1,262 to placebo. STEP 2 enrolled adults with type 2 diabetes, while STEP 1 and STEP 3 excluded people with diabetes. The pooled percentages were adjusted for differences between the trials. [2]
The US prescribing information gives the same findings as 44% and 16%, based on the people who actually received treatment (2,116 and 1,261). Those numbers differ slightly from the randomized totals. [1]
Why did a newer study report more nausea?
A separate 60-week trial published in 2026 found nausea in 53 of 72 participants on semaglutide (73.6%), compared with 12 of 48 on placebo (25.0%). It was a small study of appetite and food intake at a single center, in adults without diabetes. It adds to the evidence about how often nausea is reported, but it doesn’t replace the much larger pooled STEP data, and it doesn’t explain why the numbers differ. [6]
When does nausea peak?
Prevalence is a very specific word. What it comes down to is the share of people who have nausea at a given moment, rather than everyone who reported it at some point. In the pooled STEP 1-3 analysis, nausea prevalence peaked around week 20 and then declined. [2]
Wegovy dose and nausea over time
Weeks on treatment
That matches what the study authors describe: gastrointestinal side effects, including nausea, were most common while the dose was being increased or shortly after. [2] Because this is a pattern across the whole group, it can’t tell us how many hours after a particular injection nausea starts, or when one person’s symptoms will ease.
How long does an episode last?
The pooled analysis estimated that a single nausea episode lasted a median of eight days in the semaglutide group. That’s the midpoint: some episodes were shorter and some were longer. [2]
Median individual nausea event
8 days
The eight days describes a single episode, not how long nausea lasts for a person overall. Because someone could have more than one episode, it doesn’t tell you the total number of days they had nausea during treatment. It also doesn’t tell you how long nausea lasts after stopping the medicine.
Can nausea remain present later in treatment?
Nausea became less common over time in the pooled trials, but it didn’t go away entirely. In its review of STEP 1-3, the European Medicines Agency put nausea prevalence at week 68 at approximately 10% with semaglutide versus 1% with placebo. [3]
That’s a snapshot of who had symptoms at that point. It doesn’t mean those people had nausea for 68 weeks straight, and the data can’t tell continuous symptoms apart from a recent or returning episode.
About the week-68 figures
The EMA’s week-68 figures are approximate, and the number of people still on treatment changes over time. [3]
Had nausea at week 68 (approximate)
~10%
Semaglutide · targeting 2.4 mg
~1%
Placebo
New episodes were also recorded after the early treatment period
STEP 4 offers a second look at later nausea. Among people who had already tolerated the target dose, new nausea events were reported in 75 of 535 participants (14.0%) who stayed on semaglutide, compared with 13 of 268 (4.9%) who switched to placebo. [5]
How STEP 4 was set up
Everyone first took semaglutide for 20 weeks. Those who tolerated the target dose were then randomly assigned to keep taking it or switch to placebo. The randomized period lasted 48 weeks, with safety data collected through week 75, and events that began before randomization weren’t counted. So a new event during this period wasn’t necessarily someone’s first. [5]
Can nausea return after an episode ends?
STEP 5 shows that nausea can come back. Over 104 weeks, 81 participants on semaglutide reported 213 nausea events, while 33 participants on placebo reported 53 events. [4]
People and events are different counts
| STEP 5 | Semaglutide | Placebo |
|---|---|---|
| People reporting nausea | 81 | 33 |
| Nausea events recorded | 213 | 53 |
Since there were more events than people, some participants clearly had nausea more than once. The published counts don’t say how many people had repeat episodes, how far apart those episodes were or how many a typical person had.
What about Wegovy tablets or higher-dose injections?
Each result belongs to the formulation and the group of people it was studied in. The eight-day median episode, for example, comes from the 2.4 mg injection, so it can’t be applied to the tablet or the higher-dose injection.
Reported nausea, by study
| Study and formulation | Nausea reporting |
|---|---|
| OASIS 4 · 25 mg tablet | 47% versus 19% placebo |
| Two-trial US label pool · 7.2 mg injection | 39% at 7.2 mg; 35% at 2.4 mg; 13% placebo |
About the tablet and higher-dose studies
In OASIS 4, 204 adults without diabetes received the tablet and 102 received placebo, for up to 64 weeks with seven weeks of follow-up. The percentages shown are rounded figures for people on treatment, from FDA Table 51. [7]
The higher-dose figures come from two 72-week trials in adults with obesity, with and without type 2 diabetes: 1,311 people received 7.2 mg, 304 received 2.4 mg and 303 received placebo. Because those groups ran side by side, they allow a descriptive comparison between doses. Setting their percentages against OASIS 4 or the original STEP pool, though, doesn’t show which form causes more nausea. [1]
What the research still cannot tell us
The studies reviewed here can’t pin down exactly when nausea starts after an injection, how long recovery takes after stopping, or how likely it is to come back for any one person. A report of nausea also doesn’t mean someone has gastroparesis, and it doesn’t show what caused the nausea.
These findings come from adults in weight-management trials, so they don’t directly tell us about nausea with Ozempic, compounded semaglutide, children or people treated for MASH.
A note on overlapping data
Several findings reuse the same STEP participants, so they shouldn’t be read as separate confirmations of one another.
Safety context. Nausea rates say nothing about the risks of pancreatitis, gallbladder disease, kidney injury from fluid loss, severe gastrointestinal reactions or aspiration. The US prescribing information covers those separately, along with a boxed warning about thyroid C-cell tumors based on findings in rodents; whether that applies to humans has not been determined. [1]
When should I get help?
Get urgent care or call 911 if you have:
- Severe belly pain that doesn’t go away, with or without vomiting (it may spread to your back)
- Vomiting so often you can’t keep fluids down, or signs of dehydration like dizziness, very little urine or a racing heart
- Yellowing of your skin or eyes
Talk to a clinician soon if:
- Nausea is making it hard to eat, drink or get through your day
- It’s lasted more than a week or two, or keeps coming back
- You’re wondering whether to stay at your current dose, slow down or skip a dose. Please don’t change your dose on your own.
What does this mean for me?
Not sure which applies to you? Tell us how you’re feeling, and we’ll guide you through next steps with our licensed clinicians.
Clara is AI, not a clinician. Responses are for information, not medical advice. In an emergency, call 911.
References
- Novo Nordisk. Wegovy (semaglutide) US prescribing information. Accessed October 30, 2026. https://www.novo-pi.com/wegovy.pdf
- Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism, 24(1), 94-105. https://doi.org/10.1111/dom.14551
- European Medicines Agency (2021). Wegovy (semaglutide): EPAR public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/wegovy-epar-public-assessment-report_en.pdf
- Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S, STEP 5 Study Group (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. https://doi.org/10.1038/s41591-022-02026-4
- Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224
- Tronieri JS, Allison KC, DeRouen K, Amaro A, Collins KG, Roy A, Watts S, Ananna T, Wadden TA (2026). Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. The American Journal of Clinical Nutrition, 124(2), 101403. https://doi.org/10.1016/j.ajcnut.2026.101403
- US Food and Drug Administration (2026). Clinical review: NDA 218316, Wegovy (semaglutide) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000MedR.pdf